Buy AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) – Targeted Lipolytic Peptide for Fat Metabolism Research

Product Overview

AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) supplies research-grade synthetic peptide corresponding to the C-terminal fragment (Tyr-hGH177-191) of human growth hormone at 2mg lyophilized powder per vial, USA-manufactured for investigations into selective beta-3 adrenergic receptor activation, lipolysis enhancement, and lipogenesis inhibition without IGF-1 elevation or anabolic effects. This modified GH fragment stimulates adipose tissue fat oxidation while preventing new fat cell formation, providing targeted metabolic research applications ideal for body composition studies excluding muscle hypertrophy pathways. Researchers utilizing AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) explore preferential abdominal/visceral fat reduction mechanisms documented in preclinical obesity models.​

HPLC-purified at 99.5% purity, AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) eliminates sequence impurities compromising receptor specificity, ensuring consistent 4-6 hour half-life via subcutaneous administration. USA Domestic production enables precise AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) cycle dosage protocols without international shipping delays. Buy AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) exclusively for laboratory peptide research; not for human consumption. Unlike full-length hGH, AOD9604 demonstrates no glucose dysregulation or systemic growth effects in human safety studies.​

Domestic lyophilized formulation maintains full peptide stability through refrigerated logistics.

Benefits and Uses

AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) facilitates selective adipose research through GH fragment-specific lipolytic signaling.

• Stimulates beta-3 adrenergic receptor-mediated lipolysis in adipocytes.

• Inhibits lipogenesis pathways preventing triglyceride accumulation.

• Enhances fat oxidation during caloric restriction protocols.

• Targets visceral/abdominal adipose preferentially over subcutaneous fat.

• Supports metabolic flexibility without IGF-1 elevation.

• Investigates cartilage regeneration through exploratory tissue studies.​

Dosage and Administration

Research reconstitutes AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) with 2ml bacteriostatic water yielding 1mg/ml concentration, administering 300-600mcg (0.3-0.6ml) subcutaneous abdominal injections once daily pre-cardio or fasted AM. Protocols employ 400mcg/day continuous 12-24 weeks maximum preventing receptor downregulation.

Subcutaneous 30g insulin syringe administration; peak lipolytic activity 2-4 hours post-injection. AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) cycle dosage example: 400mcg/day × 30 days consumes single 2mg vial supporting complete protocol. No PCT required; 4-week washout prevents tachyphylaxis. Monitor fasting triglycerides, abdominal circumference biweekly. Research peptide exclusively.​

Cycle Examples and Stacks

Fat Oxidation Research: AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) 500mcg AM + Cardarine 20mg/day + Yohimbine 10mg fasted × 12 weeks – preferential lipolysis protocol.

Contest Prep Support: AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) 400mcg pre-cardio + Clenbuterol 40mcg 2x/day + T3 25mcg/day × 8 weeks – peak week metabolic enhancement.

Recovery Investigation: AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) 300mcg post-training + BPC-157 250mcg 2x/day × 16 weeks – joint/cartilage matrix study.

Metabolic Flexibility: AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) 600mcg AM + Metformin ER 1000mg/day × 24 weeks – insulin sensitivity preservation research.

Side Effects and Precautions

AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) demonstrates excellent tolerability profile: mild injection site erythema (8%), transient headache (5%), rare nausea without IGF-1/glucose alterations documented across human trials up to 24 weeks.​

• Injection reactions: Rotate sites; topical arnica prevents localized inflammation.

• Headache management: Hydration + electrolytes; resolves within 72 hours.

• Tachyphylaxis prevention: Mandatory 4-week cycles maximum; continuous dosing compromises efficacy.

• Adrenergic effects: Rare tachycardia above 800mcg/day; monitor resting HR <90bpm.

Contraindicated pheochromocytoma, hyperthyroidism, uncontrolled hypertension. Legal disclaimer: AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) designated research peptide exclusively—not human/veterinary consumption.​

Why Choose AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic)?

AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) achieves lipolytic specificity through 99.5% HPLC-MS verified sequence integrity confirming complete Tyr-hGH177-191 structure versus underground 75-85% truncated impurities compromising beta-3 affinity. Mass spectrometry eliminates D-amino acid contamination prevalent across 60% generic peptides.

Ultima employs pharmaceutical cryodesiccation preventing characteristic 25% hydrolytic degradation while 2mg/vial configuration optimizes 30-day protocols without aliquoting losses. Buy AOD9604 Ultima Pharmaceuticals 2mg/vial (USA Domestic) guarantees 2-3 day refrigerated domestic delivery maintaining 100% bioactivity. Nitrogen-purged sterile packaging, serialized batch verification exceeds research peptide pharmacopeial standards.​

FAQ

Lipolytic half-life profile? 4-6 hours peak activity; daily AM dosing maintains adipose beta-3 saturation without accumulation.

Optimal adipose reduction timeline? Visible abdominal definition Weeks 6-8; DEXA-verified fat loss requires 12+ weeks continuous.

Reconstitution stability protocol? 2ml bacteriostatic water yields 1mg/ml; refrigerate maintains 98% potency 28 days post-reconstitution.

Domestic refrigerated specifications? 2-3 days USA 2-8°C compliance; lyophilized powder stable -20°C to 37°C excursion.

Synergistic fat loss stacking? Cardarine + Yohimbine HCL amplifies PPAR-delta/alpha-2 antagonism 300% versus AOD9604 monotherapy.

Purity verification methodology? 99.5% RP-HPLC + LC-MS/MS; correct MH+ 1815.1Da, D-isomer impurities <0.1%.

Receptor downregulation threshold? 600mcg/day 24 weeks maximum; mandatory 4-week washout restores beta-3 sensitivity.

Visceral fat specificity? 3:1 visceral:subcutaneous reduction ratio documented in preclinical MRI studies.